SEC Form 4/A · accession 0001387131-17-005086
Ohr Pharmaceutical Inc · OHRP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
This is an amendment (Form 4/A). It replaces an earlier filing for the same period.
Reporting owner
Michael Ferguson
Director
Period of report
May 12, 2017
Accepted (ET)
Oct 18, 2017 · 6:00 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001173281
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1,F2 | $0.65 | May 12, 2017 | A | 500,000 | A | — | May 11, 2022 | Common Stock | 500,000 | 500,000 | D |
Explanation of responses
- F1Reflects a reduction of options to purchase 250,000 shares of common stock subject to the stock option, the excess portion of shares of common stock subject to the stock options granted to the reporting person on May 12, 2017, in connection with the reporting person's appointment to the board of directors of the Issuer, which excess portion has been determined to have been in excess of annual plan limits set forth in the Issuer's 2016 Consolidated Stock Incentive Plan, and thus rescinded and canceled.
- F2250,000 shares of common stock subject to the stock option became exercisable immediately, and 125,000 shares of common stock subject to the stock option will become exercisable on each of May 12, 2018 and May 12, 2019.